Clinical trial

A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

NCT00739453

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2008-10-23

PhasePHASE1

Study timeline

Study start (actual)2008-10-23Date precision: day

Registry last updated2024-11-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Solid Tumorsunresolved

Interventions

OSI-906DRUG

erlotinibDRUG · verified · RxNorm: erlotinib

Sponsors & collaborators

Astellas Pharma Inclead sponsor

Mapped research locations

BaltimoreMaryland, United States1 AuroraColorado, United States1 DetroitMichigan, United States1 OxfordUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00739453 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.